JP2021500035A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500035A5 JP2021500035A5 JP2020522356A JP2020522356A JP2021500035A5 JP 2021500035 A5 JP2021500035 A5 JP 2021500035A5 JP 2020522356 A JP2020522356 A JP 2020522356A JP 2020522356 A JP2020522356 A JP 2020522356A JP 2021500035 A5 JP2021500035 A5 JP 2021500035A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- seq
- amino acid
- signal peptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 7
- 241000186660 Lactobacillus Species 0.000 claims 7
- 229940039696 lactobacillus Drugs 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 3
- 108090000174 Interleukin-10 Proteins 0.000 claims 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims 3
- 239000006143 cell culture medium Substances 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 102000046975 human DEFB1 Human genes 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241000186606 Lactobacillus gasseri Species 0.000 claims 1
- 108010090763 Shiga Toxin 2 Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575350P | 2017-10-20 | 2017-10-20 | |
| US62/575,350 | 2017-10-20 | ||
| US201762584367P | 2017-11-10 | 2017-11-10 | |
| US62/584,367 | 2017-11-10 | ||
| US201862676203P | 2018-05-24 | 2018-05-24 | |
| US62/676,203 | 2018-05-24 | ||
| US201862691553P | 2018-06-28 | 2018-06-28 | |
| US62/691,553 | 2018-06-28 | ||
| PCT/US2018/056610 WO2019079663A1 (en) | 2017-10-20 | 2018-10-19 | ARTIFICIAL SECRETING PEPTIDES FOR THE PRODUCTION OF HETEROLOGOUS PROTEINS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500035A JP2021500035A (ja) | 2021-01-07 |
| JP2021500035A5 true JP2021500035A5 (enExample) | 2021-12-02 |
| JP7330517B2 JP7330517B2 (ja) | 2023-08-22 |
Family
ID=66173492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522356A Active JP7330517B2 (ja) | 2017-10-20 | 2018-10-19 | 異種タンパク質産生のための人工分泌ペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11530433B2 (enExample) |
| EP (1) | EP3697428A4 (enExample) |
| JP (1) | JP7330517B2 (enExample) |
| KR (1) | KR20200077534A (enExample) |
| CN (1) | CN111491657A (enExample) |
| WO (1) | WO2019079663A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022198019A1 (en) * | 2021-03-19 | 2022-09-22 | Tenza, Inc. | Synthetic pre-protein signal peptides for directing secretion of heterologous proteins in bacillus bacteria |
| WO2023220708A2 (en) * | 2022-05-12 | 2023-11-16 | Tenza, Inc. | Synthetic pre-protein signal peptides for directing secretion of heterologous proteins in escherichia bacteria |
| DE102022119024A1 (de) * | 2022-07-28 | 2024-02-08 | INM - Leibniz-Institut für Neue Materialien gemeinnützige Gesellschaft mit beschränkter Haftung | Neuartige genetische Werkzeuge |
| JP2026502916A (ja) * | 2022-12-30 | 2026-01-27 | テンザ、インク． | 異種タンパク質産生のための人工分泌ペプチド |
| WO2025146497A1 (en) * | 2024-01-05 | 2025-07-10 | National University Of Singapore | Methods for drug delivery |
| CN118813504B (zh) * | 2024-09-19 | 2025-02-07 | 青岛诺和诺康生物科技有限公司 | 改善血栓和血管健康的卷曲乳杆菌及其制品和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| US6093394A (en) | 1997-04-11 | 2000-07-25 | Gynelogix, Inc. | Vaginal lactobacillus medicant |
| JP2002017357A (ja) * | 2000-07-04 | 2002-01-22 | Calpis Co Ltd | アンカーペプチド、融合蛋白質、及び蛋白質の固定化方法 |
| US7179458B2 (en) | 2002-03-08 | 2007-02-20 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
| EP1915174A1 (en) | 2005-08-19 | 2008-04-30 | Unilever N.V. | Food products comprising probiotic micro-organisms and antibodies |
| US20080051317A1 (en) | 2005-12-15 | 2008-02-28 | George Church | Polypeptides comprising unnatural amino acids, methods for their production and uses therefor |
| US20110104121A1 (en) | 2008-05-21 | 2011-05-05 | Wira Charles R | Female Reproductive Tract and Anal Prophylaxes |
| GB0821729D0 (en) * | 2008-11-28 | 2008-12-31 | Plant Bioscience Ltd | Composition and method for enhanced secretion of peptides and proteins from bacteria |
| WO2010077682A2 (en) | 2008-12-08 | 2010-07-08 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
| US9073990B2 (en) | 2010-04-05 | 2015-07-07 | Bar-Llan University | Protease-activatable pore-forming polypeptides |
| US20130164380A1 (en) | 2010-06-17 | 2013-06-27 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
| GB2482536B (en) | 2010-08-05 | 2013-07-24 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
| CN104781401B (zh) | 2012-10-26 | 2018-06-05 | 独立行政法人产业技术综合研究所 | 人工生物发光酶 |
| ES3057033T3 (en) | 2014-01-31 | 2026-02-25 | Cytomx Therapeutics Inc | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| JP7632835B2 (ja) | 2016-05-20 | 2025-02-19 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 加齢関連疾患及び症状の遺伝子治療法 |
| IL265177B2 (en) * | 2016-09-13 | 2025-01-01 | Intrexon Actobiotics N V | A microorganism that adheres to the mucosa |
-
2018
- 2018-10-19 US US16/757,687 patent/US11530433B2/en active Active
- 2018-10-19 WO PCT/US2018/056610 patent/WO2019079663A1/en not_active Ceased
- 2018-10-19 EP EP18869030.9A patent/EP3697428A4/en not_active Withdrawn
- 2018-10-19 JP JP2020522356A patent/JP7330517B2/ja active Active
- 2018-10-19 KR KR1020207014298A patent/KR20200077534A/ko not_active Ceased
- 2018-10-19 CN CN201880081319.8A patent/CN111491657A/zh active Pending
-
2022
- 2022-11-14 US US18/055,044 patent/US20230257794A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500035A5 (enExample) | ||
| Ribelles et al. | Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface | |
| JP2014503198A5 (enExample) | ||
| US20230257794A1 (en) | Artificial secretion peptides for heterologous protein production | |
| JP2013107899A5 (enExample) | ||
| JP2016508143A5 (enExample) | ||
| CN103130894B (zh) | 抗人γδTCR单克隆抗体的重组单链抗体G5‑4ScFv及其编码基因与应用 | |
| CN117986360B (zh) | Il18蛋白的特异性抗体及其制备方法与应用 | |
| WO2023165502A1 (zh) | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 | |
| CN103193887A (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
| CN104845981A (zh) | 田鼠巴贝虫Bm1524抗原及其应用 | |
| CN118530314B (zh) | 广谱型流感疫苗抗原片段、重组益生菌及应用 | |
| CN103173478B (zh) | 一种携带ptd的抗人cd3单链抗体的制备方法 | |
| CN102901826A (zh) | 人类潜在新细胞因子tmem98及其用途 | |
| Zhang et al. | Nanobodies in cytokine‑mediated immunotherapy and immunoimaging | |
| CN118176207A (zh) | 靶向细胞疗法 | |
| CN115125215B (zh) | 分泌猪IFN-λ4单克隆抗体的杂交瘤细胞株及其分泌的单克隆抗体与应用 | |
| CN115850520A (zh) | 新型结核病亚单位疫苗al的制备方法和应用 | |
| CN103524625B (zh) | 一种新型诱导抗体产生的方法 | |
| CN112457391A (zh) | 猪干扰素α、β、λ1在酿酒酵母中共分泌表达的方法及其应用 | |
| CN120842388B (zh) | 一种靶向血清白蛋白纳米抗体的纳米抗体3h8及其衍生物和应用 | |
| CN120842389B (zh) | 一种抗血清白蛋白纳米抗体1b7及其在延长多肽药物半衰期中的应用 | |
| Wu et al. | Identification of BPI protein produced in different expression system and its association with Escherichia coli F18 susceptibility | |
| Umami et al. | Cloning and Expression of HBcAg Using Food Grade Vector pNZ8149 in Lactococcus Lactis for the Development of HBV Therapeutic Vaccine | |
| CN106397587A (zh) | 一种全人源抗MAGEA3的全分子IgG抗体及其应用 |